[HTML][HTML] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
[HTML][HTML] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo-Davo, D Flumens… - Journal of …, 2022 - ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo-Davo… - Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
G Roex, D Campillo-Davo, D Flumens… - Journal of …, 2022 - europepmc.org
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
[HTML][HTML] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo-Davo… - Journal of …, 2022 - … -medicine.biomedcentral.com
Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable new treatment
option for patients with B-cell malignancies. However, by applying selective pressure …
option for patients with B-cell malignancies. However, by applying selective pressure …
[PDF][PDF] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo‑Davo, D Flumens, PAG Shaw… - 2022 - academia.edu
Background: Chimeric antigen receptor (CAR) T‑cell therapy has proven to be a valuable
new treatment option for patients with B‑cell malignancies. However, by applying selective …
new treatment option for patients with B‑cell malignancies. However, by applying selective …
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo-Davo… - Journal of …, 2022 - repository.uantwerpen.be
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
G Roex, D Campillo-Davo, D Flumens… - Journal of …, 2022 - europepmc.org
Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …
new treatment option for patients with B-cell malignancies. However, by applying selective …
[PDF][PDF] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo‑Davo, D Flumens… - 2022 - … -medicine.biomedcentral.com
Background: Chimeric antigen receptor (CAR) T‑cell therapy has proven to be a valuable
new treatment option for patients with B‑cell malignancies. However, by applying selective …
new treatment option for patients with B‑cell malignancies. However, by applying selective …
[PDF][PDF] Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
G Roex, D Campillo‑Davo, D Flumens, PAG Shaw… - 2022 - repository.uantwerpen.be
Background: Chimeric antigen receptor (CAR) T‑cell therapy has proven to be a valuable
new treatment option for patients with B‑cell malignancies. However, by applying selective …
new treatment option for patients with B‑cell malignancies. However, by applying selective …